Author:
Glass B,Nickelsen M,Dreger P,Claviez A,Hasenkamp J,Wulf G,Trümper L,Schmitz N
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference24 articles.
1. Blay J, Gomez F, Sebban C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998; 92: 3562–3568.
2. Guglielmi C, Gomez F, Philip T et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 1998; 16: 3264–3269.
3. Verdonck LF, Dekker AW, Lokhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201–4205.
4. Glass B, Ruiz de Elvira C, Schmitz N . Salvage therapy after high-dose therapy (HDT) and autologous stem cell transplantation (SCT): allogeneic or autologous second transplant in lymphoma, a retrospective analysis of the EBMT. Bone Marrow Transplant 2002; 29 (Suppl. 2) (Abstract).
5. Bertz H, Illerhaus G, Veelken H, Finke J . Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann Oncol 2002; 13 (1): 135–139.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献